1. Home
  2. XYF vs IMUX Comparison

XYF vs IMUX Comparison

Compare XYF & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

XYF

X Financial each representing six

HOLD

Current Price

$5.04

Market Cap

186.4M

Sector

Finance

ML Signal

HOLD

Logo Immunic Inc.

IMUX

Immunic Inc.

HOLD

Current Price

$11.00

Market Cap

152.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XYF
IMUX
Founded
2014
2016
Country
China
United States
Employees
N/A
66
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
186.4M
152.6M
IPO Year
2018
2013

Fundamental Metrics

Financial Performance
Metric
XYF
IMUX
Price
$5.04
$11.00
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$36.00
AVG Volume (30 Days)
133.7K
2.2M
Earning Date
05-18-2026
05-14-2026
Dividend Yield
11.34%
N/A
EPS Growth
N/A
38.00
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$0.90
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.30
$0.51
52 Week High
$20.36
$11.29

Technical Indicators

Market Signals
Indicator
XYF
IMUX
Relative Strength Index (RSI) 59.05 85.94
Support Level $4.86 $0.75
Resistance Level $5.07 N/A
Average True Range (ATR) 0.21 0.65
MACD 0.02 0.82
Stochastic Oscillator 91.93 97.85

Price Performance

Historical Comparison
XYF
IMUX

About XYF X Financial each representing six

X Financial is a Cayman Islands-based technology-driven personal finance company. Along with its subsidiaries, the firm provides diversified investment opportunities to investors in China through its wealth management platform, Xiaoying Wealth Management. Loan products offered by the company include Xiaoying Card Loan, Xiaoying Preferred Loan, and Xiaoying Housing Loan. The company generates revenue from loan facilitation service, post-origination service, and guarantee services provided.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.

Share on Social Networks: